The U.S. Food and Drug Administration has given emergency approval to the vaccine developed by Johnson and Johnson, giving America a third vaccine in its fight against the virus.
The J&J vaccine can be administered in just one dose, though they're studying the impact of giving a second one.
The company says it expects that 20 million doses will be available by the end of March.
An analysis by the FDA found it to be 86 percent effective against severe disease and 72 percent effective against moderate to severe disease.
Those numbers, however, were lower for the South Africa variant.